Privia Health Group, Inc.
NASDAQ:PRVAMedical - Healthcare Information Services
+$0.15 today
- Market cap
- $3.14B
- Beta
- 0.87
- P/E (TTM)
- 134.4
- EPS (TTM)
- $0.18
Volume 2.38M
Average 0.95M
PRVA Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Privia Health Group, Inc.NASDAQ: PRVA
Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026
Income tax expense growth accelerates
Q2 FY2026 income tax expense of $7.02M rose 185.7% year over year, ahead of the +98.6% change in trailing-twelve-month income tax expense. Sequentially, it rose 25.3% from the prior quarter.
Context
- Income tax expense amounted to 0.7% of revenue in FY2025, unchanged from a year earlier.
- Income tax expense increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +185.7% holds above the trailing-twelve-month pace of +98.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 14.21M USD
- Year-over-year change
- +31.3%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.21M | +31.3% |
| FY2024 | 2024-12-31 | 10.83M | +35.4% |
| FY2023 | 2023-12-31 | 7.99M | +222.7% |
| FY2022 | 2022-12-31 | (6.52M) | +76.6% |
| FY2021 | 2021-12-31 | (27.86M) | — |
Income Tax Expense vs competitors
How PRVA compares with its peers on the latest reported figures
- PRVA's LTM Jun 2026 income tax expense of $22.27M is the highest of the 10 companies compared; the peer median is $83K.
- Its year-over-year change of +98.6% is the 2nd highest of 9, against a peer median of -33.0%.
- Income tax expense amounts to 0.9% of revenue for PRVA, versus a peer median of 0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $22.27M | +98.6% | — | 0.9% | |
| LTM Mar 2026 | $18.73M | -31.0% | -27.6% | 0.5% | |
| LTM Mar 2026 | $1.03M | -42.3% | -8.6% | 0.0% | |
| LTM Mar 2026 | $915K | +110.3% | — | 0.3% | |
| LTM Mar 2026 | $210K | +29.6% | +4.0% | 0.2% | |
| LTM Mar 2026 | $83K | -95.9% | +89.3% | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | -$686K | -35.0% | — | 0.0% | |
| LTM Apr 2026 | -$10.22M | -447.5% | — | 2.1% | |
| LTM Mar 2026 | -$13.96M | -4.5% | — | 0.6% | |
| Peer median (excluding PRVA) | $83K | -33.0% | -2.3% | 0.2% | |
Competitors are the stored peer set for PRVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 966.22M | 1.36B | 1.66B | 1.74B | 2.12B |
| Cost of Revenue | 902.56M | 1.22B | 1.5B | 1.56B | 1.91B |
| Gross Profit | 63.66M | 134.78M | 161.5M | 176.85M | 209.43M |
| Gross Margin | 6.6% | 9.9% | 9.7% | 10.2% | 9.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 278.63M | 149.33M | 134.32M | 152.6M | 165.29M |
| Operating Expenses | 281.1M | 153.9M | 140.85M | 159.87M | 175.2M |
| Depreciation & Amortization | 2.46M | 4.57M | 6.53M | 7.27M | 9.91M |
| EBITDA | (214.97M) | (14.01M) | 35.55M | 35.14M | 53.85M |
| EBITDA Margin | -22.2% | -1.0% | 2.1% | 2.0% | 2.5% |
| Operating Income | (217.44M) | (19.12M) | 20.65M | 16.98M | 34.24M |
| Operating Margin | -22.5% | -1.4% | 1.2% | 1.0% | 1.6% |
| Interest Income | 0 | 542K | 8.37M | 10.89M | 9.7M |
| Interest Expense | 1.07M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.07M) | 542K | 8.37M | 10.89M | 9.7M |
| Income Before Tax | (218.51M) | (18.58M) | 29.02M | 27.87M | 43.94M |
| Pre-Tax Margin | -22.6% | -1.4% | 1.8% | 1.6% | 2.1% |
| Income Tax Expense | (27.86M) | (6.52M) | 7.99M | 10.83M | 14.21M |
| Net Income | (188.23M) | (8.59M) | 23.08M | 14.39M | 22.92M |
| Net Margin | -19.5% | -0.6% | 1.4% | 0.8% | 1.1% |
| EPS (Basic) | (1.77) | (0.08) | 0.20 | 0.12 | 0.19 |
| EPS (Diluted) | (1.77) | (0.08) | 0.19 | 0.11 | 0.18 |
| Weighted Avg Shares | 107.84M | 110.7M | 116.73M | 119.4M | 122.18M |
| Weighted Avg Shares (Diluted) | 107.84M | 110.7M | 124.69M | 125.61M | 128.89M |
Privia Health Group, Inc.
NASDAQ:PRVA
Intrinsic Alpha fair value
Locked
Current Price
$24.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.